Clinical Trials for Obesity

645 obesity trials indexed, 252 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding Obesity

Obesity is a medical condition characterized by excessive body fat accumulation that may impair health. It results from an energy imbalance where calorie intake exceeds calorie expenditure over time. The underlying biology involves complex interactions between genetics, metabolism, environment, and behavior. Hormones like leptin and insulin play key roles in regulating hunger and fat storage. Clinicians typically diagnose obesity using the body mass index (BMI), which is a ratio of weight to height squared. A BMI of 30 or higher is generally considered obese. Additional assessments may include waist circumference and body fat percentage to evaluate health risks more precisely.

Common symptoms of obesity include increased body weight and fat deposits, especially around the abdomen. Individuals may experience reduced stamina, joint pain, and difficulties with physical activity. While obesity can develop at any age, it often begins in childhood or early adulthood. Certain groups are more affected, including those with sedentary lifestyles, poor dietary habits, or genetic predispositions. Risk factors include high-calorie diets, lack of exercise, certain medications, and socioeconomic status. Obesity rates tend to be higher in some ethnic groups and in areas with limited access to healthy food options.

Obesity is a major medical and social concern because it increases the risk of many chronic diseases. These include type 2 diabetes, heart disease, stroke, and certain cancers. Socially, obesity can lead to stigma and reduced quality of life. According to the Centers for Disease Control and Prevention, about 42.4% of adults in the United States were obese in 2017-2018. This high prevalence contributes significantly to healthcare costs and lost productivity. The World Health Organization estimates that obesity-related conditions account for millions of deaths worldwide each year, highlighting the need for effective management and prevention strategies.

The Obesity Treatment Landscape

The first-line treatment for obesity usually starts with lifestyle modifications. These include dietary changes, increased physical activity, and behavioral counseling. Healthcare providers often recommend a calorie-restricted diet combined with regular exercise tailored to the individual’s abilities. Weight loss goals are typically modest, aiming for a 5-10% reduction in body weight to improve health outcomes. If lifestyle changes alone are insufficient, clinicians may consider more intensive interventions. Ongoing support and monitoring are important to help patients maintain weight loss and prevent relapse.

When lifestyle interventions do not achieve desired results, second-line treatment options often involve pharmacotherapy. Several drug classes are approved for obesity management, including appetite suppressants, lipase inhibitors, and medications that affect metabolism. Examples of established drugs include orlistat, which reduces fat absorption, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that promotes satiety. In some cases, third-line options such as bariatric surgery may be recommended for individuals with severe obesity or related health complications. Surgery types include gastric bypass and sleeve gastrectomy, which physically limit food intake or absorption.

Despite available treatments, significant gaps remain. Some patients respond poorly to existing therapies or experience side effects that limit their use. For example, gastrointestinal symptoms are common with orlistat, and some weight loss drugs can affect mood or cardiovascular health. Resistance to weight loss efforts is also a challenge, as the body’s metabolism may adapt to conserve energy. Current research focuses on developing new medications with better safety profiles and targeting different biological pathways. There is also interest in personalized approaches that consider genetic and metabolic differences among patients.

Why Clinical Trials Matter for Obesity

Clinical trials offer important opportunities for patients with obesity. Participating in a trial can provide access to new treatments that are not yet widely available. Patients also receive closer medical monitoring than in standard care, which can help manage health conditions related to obesity. By joining a trial, individuals contribute to scientific knowledge that may improve future therapies. Currently, ClinicalTrials.gov lists 645 obesity clinical trials, with 252 actively recruiting participants. This large number reflects ongoing efforts to find better ways to treat and understand obesity.

It is important to understand the potential risks involved in clinical trials. The effectiveness of new treatments is not guaranteed, and some participants may receive a placebo instead of the active drug. Trials often require additional clinic visits, tests, and procedures, which can be time-consuming. Side effects may occur, especially with experimental medications, and these need to be carefully monitored. Patients should discuss these factors thoroughly with their healthcare providers before enrolling to make informed decisions.

The sponsors of obesity clinical trials include academic institutions, pharmaceutical companies, and cooperative research groups. Each plays a role in advancing knowledge and developing new therapies. ClinicalTrials.gov serves as a comprehensive registry where patients and caregivers can find detailed information about ongoing studies. This transparency helps individuals identify trials that may fit their needs and supports ethical standards in research. Overall, the clinical trial system is a key part of improving care for people affected by obesity.

What to Look for in a Obesity Clinical Trial

Clinical trials are divided into four main phases. Phase 1 tests a new treatment for safety in a small group of people. Phase 2 looks at how well the treatment works and further evaluates safety. Phase 3 compares the new treatment to standard treatments in larger groups. Phase 4 happens after approval to monitor long-term effects. For obesity trials, many studies do not specify a phase, with 307 listed as NA. Phase 2 trials are the most common at 60, followed by 55 in Phase 1 and 54 in Phase 3. This shows a focus on testing effectiveness and safety in moderate-sized groups.

Inclusion criteria for obesity trials often focus on specific age ranges, usually adults between 18 and 65 years. Some trials may include adolescents or older adults depending on the study goals. Prior treatments might be considered, such as whether participants have tried diet, exercise, or medications before. Biomarkers like blood sugar or cholesterol levels could be used to select participants. Staging of obesity, usually by body mass index (BMI), is important to define the severity. Disease duration or how long a person has been obese may also be part of the criteria.

Exclusion criteria help protect participants and ensure clear results. People with certain comorbidities like uncontrolled diabetes, heart disease, or severe mental illness may be excluded due to safety concerns. Potential drug interactions with current medications are considered to avoid harmful effects. Safety thresholds such as liver or kidney function tests may exclude participants if values are too abnormal. These rules aim to reduce risks and make sure the study results apply to a specific group of people.

From a patient perspective, practical details matter. Trial duration can range from a few weeks to several months or longer. Visit schedules may require frequent in-person appointments for tests and monitoring. Travel to the trial site might be needed, which can be a burden for some. When talking to the research team, ask these questions: How long will the study last? What kind of visits and tests are required? Are there any costs or reimbursements? What happens if I want to leave the study early? Understanding these details helps participants make informed decisions.

Primary Sources and Further Reading

For more information about obesity and clinical trials, it is helpful to consult trusted sources. These websites provide reliable details on obesity research, treatment options, and how clinical trials work. They also offer guidance for patients considering participation in studies. Here are some key resources to explore.

Latest Research and Emerging Treatments for Obesity (2026)

Obesity research in 2026 is focusing on new drugs that may offer more options for managing weight safely and effectively. One promising area involves drugs like cagrilintide and semaglutide, which are being tested in children and adolescents with excess body weight (NCT07253285). These medications work by affecting appetite and digestion, helping to reduce hunger and calorie intake. If successful, they could provide younger patients with obesity new treatment choices that fit their specific needs and support healthier growth.

For adults, several trials are exploring different approaches to obesity treatment. Retatrutide and tirzepatide are two injectable drugs being compared for their ability to lower body weight (NCT06662383). Both belong to a class of medications that influence hormones related to blood sugar control and appetite. Another study is testing survodutide, which may help people with obesity who also have heart or kidney problems by potentially reducing serious cardiovascular events (NCT06077864). These treatments aim to improve overall health while addressing weight, which could change how patients manage obesity alongside other conditions.

Orforglipron is an oral medication under study for people with type 2 diabetes and obesity or overweight at increased cardiovascular risk (NCT05803421). It offers a pill alternative to injectable drugs like insulin, which might make treatment easier for some patients. Additionally, MET097, a once-weekly injectable drug, is being tested for adults with overweight or obesity to see if it can help control weight and related health issues (NCT07311850). These new drugs for obesity represent ongoing efforts to expand treatment options with different methods of delivery and mechanisms of action. For patients, this research could mean more personalized and convenient obesity treatment choices in the near future.

Frequently asked questions about Obesity trials

How do I find Obesity clinical trials?

The authoritative source for Obesity clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 645 obesity studies are currently indexed. You can search by entering "obesity" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new obesity trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most Obesity trials in?

Across the 645 obesity trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many Obesity clinical trials are currently recruiting?

As of the latest scan, 252 obesity trials have a "Recruiting" status on ClinicalTrials.gov, out of 645 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting obesity trial matches their tracked condition.

Stay informed about obesity research

Get a weekly briefing with the trials that matter most.

Start monitoring obesity trials